Study of early plasma cell blood conditions before myeloma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM).
- For MGUS: your monoclonal protein is below thresholds and your bone marrow plasma cell percentage is under 10%, and you do not have myeloma- or amyloidosis-related events.
- For SMM: your monoclonal protein and/or bone marrow plasma cell percentage is at intermediate levels, and you do not have myeloma- or amyloidosis-related events.
- Your blood tests and scans do not show “myeloma-defining” problems (like certain kidney, blood, bone, calcium, or high light-chain findings, or many/big spots on MRI).
- You have not had chemotherapy or investigational medicines for these early conditions (bisphosphonates are allowed; radiotherapy is not).
- You can attend visits and have no uncontrolled ongoing illness (like an active infection) that would make follow-up hard.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study is collecting blood samples from people with plasma cell disorders to help researchers learn more about these conditions. It may be a good fit if you haven't started treatment yet and are willing to donate samples.
Hear when a new Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.